Cambrex Corporation has announced its acquirement of PharmaCore for a purchase consideration of $25 million.
Wombat Capital Markets is acting as advisor to PharmaCore for the acquisition, which is expected to be completed by October 2016.
The acquisition will enable Cambrex to expand its product portfolio in the US and European markets.
Sichuan Kelun Pharmaceutical has announced it will acquire an 80% stake in an unrevealed biotechnology company.
The company expects that the acquisition will cost them up to $9.59 million.